Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites-Reference-Cited by-同舟云学术

Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites

Published:2018-12-10 Issue:3 Volume:74 Page:699-709
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Decloedt Eric H¹²,Sinxadi Phumla Z²,van Zyl Gert U³,Wiesner Lubbe²,Khoo Saye⁴,Joska John A⁵,Haas David W⁶⁷,Maartens Gary²

Affiliation:

1. Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

2. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa

3. Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University and National Health Laboratory Service, Cape Town, South Africa

4. Institute of Translational Medicine, University of Liverpool and Royal Liverpool University Hospital, Liverpool, UK

5. Division of Neuropsychiatry, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa

6. Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA

7. Department of Internal Medicine, Meharry Medical College, Nashville, TN, USA

Funder

South African Medical Research Council

European and Developing Countries Clinical Trials

National Institute of Allergy and Infectious Diseases of the National Institutes of Health

National Institute of Child Health and Human Development

National Institute of Mental Health

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)

Link

http://academic.oup.com/jac/article-pdf/74/3/699/27785445/dky481.pdf

Reference47 articles.

1. Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?;Underwood;AIDS,2015

2. Antiretroviral neurotoxicity;Robertson;J Neurovirol,2012

3. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort;Robertson;Neurology,2010

4. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study;Winston;Clin Infect Dis,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa (CONNECT): a prospective cohort study;The Lancet HIV;2024-09

2. Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV;International Journal of Antimicrobial Agents;2024-06

3. Influence of efavirenz and 8‐hydroxy‐efavirenz plasma levels on cognition and central nervous system side effects;HIV Medicine;2023-12-17

4. Pharmacogenomics and adverse effects of anti‐infective drugs in children;Clinical and Experimental Pharmacology and Physiology;2023-10-15

5. Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update;Current Drug Metabolism;2023-07